
## (12) INTERNATIONAL A

# CATION PUBLISHED UNDER THE PATENT C



# (19) World Intellectual Property Organization

International Bureau





(10) International Publication Number PCT WO 2004/003005 A2

(51) International Patent Classification7:

**C07K** 

(21) International Application Number:

PCT/US2003/019987

(22) International Filing Date: 26 June 2003 (26.06.2003)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data: 60/392,028

28 June 2002 (28.06.2002)

(71) Applicant (for all designated States except US): THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SER-VICES [US/US]; 6011 Executive Boulevard, Suite 325, Rockville, MD 20852-3804 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): BURKE, Terrence, R., Jr. [US/US]; 7400 Lakeview Drive, Bethesda, MD 20817 (US). WEI, Chang-Qing [CN/CA]; 290 Nelson Street, Apt #404, Ottawa, Ontario K1N 7S3 (CA). VOIGT, Johannes, H. [DE/US]; 525 Quinton Avenue, Kenilworth, NJ 07033 (US). SHI, Zhen-Dan [US/US]; 1418A Taney Avenue, No. 204, Frederick, MD 21702 (US). GAO, Yang [CN/US]; 62 Montoya Circle, Branford, CT 06405 (US).


- (74) Agent: PILLAI, Xavier; Leydig, Voit & Mayer, 700 Thirteenth Street, NW, Suite 300, Washington, DC 20005 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

### Published:

without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: SH2 DOMAIN BINDING INHIBITORS



Concentration of inhibitors(uM)

(57) Abstract: Disclosed compounds for SH2 domain binding inhibition, for example, a compound of formula (I), wherein R<sub>1</sub> is a lipophile; R<sub>2</sub>, in combination with the phenyl ring, is a phenylphosphate mimic group or a protected phenylphosphate mimic group; R<sub>3</sub> is hydrogen, azido, amino, carboxyalkyl, alkoxycarbonylalkyl, aminocarbonylalkyl, or alkylcarbonylamino, wherein the alkyl portion of R<sub>3</sub> may be optionally substituted with a substituent selected from the group consisting of halo, hydroxy, carboxyl, amino, aminoalkyl, alkyl, alkoxy, and keto; R6 is a linker; AA is an amino acid; and n is 1 to 6; or a salt thereof. conformationally compounds provide enhanced binding affinity with SH2 domain protein. Also disclosed are a pharmaceutical compositions and a method for inhibiting an SH2 domain from binding with a phosphoprotein.

